Sales Nexus CRM

MindBio's AI Voice Technology Hits 83% Accuracy in Intoxication Detection, Eyes Commercial Pilot

By FisherVista•
MindBio Therapeutics reports up to 83% accuracy in AI-driven intoxication detection and announces a CA$350,000 private placement to support its first commercial pilot.
MindBio's AI Voice Technology Hits 83% Accuracy in Intoxication Detection, Eyes Commercial Pilot

MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) announced that its artificial intelligence (AI)-driven voice analytics technology is nearing final product testing ahead of its first commercial pilot, with intoxication detection accuracy reaching up to 83% under certain testing conditions. The company reported that its prediction models, tested with and without sober baseline tracking, have exceeded the accuracy of some commercially available cheek swab tests.

The technology, which uses over 50 million data points to predict alcohol intoxication through voice analysis, is being developed for enterprise environments including mining, aviation, construction, and law enforcement. MindBio plans to conduct additional human testing over the next two to three weeks before launching its first commercial pilot. The initial commercially ready product is expected to integrate proprietary Voice AI software with the company's previously announced Edge AI Intoxication Detection Kiosk, initially operating in Spanish.

This development matters because workplace intoxication testing is traditionally invasive and time-consuming. A voice-based solution could offer a faster, non-invasive alternative, potentially improving safety and efficiency in high-risk industries. The reported accuracy, if validated in further testing, could position MindBio's technology as a competitive tool in the growing market for alcohol and drug detection.

Separately, MindBio announced a nonbrokered private placement of up to 3,888,889 units at $0.09 per unit for gross proceeds of up to CA$350,000. Each unit will consist of one common share and one-half of a common share purchase warrant, with each whole warrant exercisable at $0.16 per share for 36 months following closing. Proceeds are intended to support general working capital, annual audit and legal expenses, and OTC and CSE listing costs.

The private placement signals the company's need for additional capital as it moves toward commercialization. For investors, the financing could be dilutive, but it also provides resources to advance the pilot and cover regulatory costs. The announcement comes as MindBio seeks to commercialize its AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for detection in a range of enterprise environments.

For more details, the full press release is available at https://ibn.fm/ErHN1, and the latest news and updates relating to MBQIF can be found in the company's newsroom at https://ibn.fm/MBQIF. The announcement was disseminated on behalf of MindBio Therapeutics Corp. through TechMediaWire, a specialized communications platform focused on pioneering companies driving the future of technology. TechMediaWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire and other services. Readers should review the full terms of use and disclaimers at https://www.TechMediaWire.com/Disclaimer.

FisherVista

FisherVista

@fishervista